April 16, 2018

Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights

DUBLIN, Ohio–(BUSINESS WIRE)–$NAVB–Navidea Biopharmaceuticals (NYSE MKT:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it has signed a deal to provide Meilleur Technologies, Inc.,(Meilleur) a wholly owned subsidiary of Cerveau Technologies, Inc. (Cerveau), worldwide rights to conduct research using NAV4694, a beta-amyloid imaging agent being evaluated as an aid in the differential diagnosis of ear


Leave Comment


Your Name *
Your Email *
Your Website
Comment *